{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '1. Joint assessor will be independent to the rest of the study team. An independent joint assessor, blinded to other study assessments as well as the', 'dosing', 'regimen, will be identified at each study site to perform the SJC and TJC. To ensure consistent joint evaluation throughout the study, individual subjects', 'should be evaluated by the same joint assessor as in the core studies for all study visits whenever possible.', 'm. Starting at Visit 4 (Week 36) and then at all onsite visits until the end of the open-label Treatment Period (Visit 10 [EoT/Week 106]), all subjects will be', 'assessed for response to treatment, with nonresponders defined as subjects who do not improve by at least 20% in SJC and TJC (66-68 joint assessment)', 'from the Core Baseline assessment.', 'n.', 'Adverse events and SAEs are reported from OLE Baseline.', 'o.', 'At scheduled visits, IGRA testing should be performed only for subjects who had a negative IGRA result at the previous assessments (including', 'Week 22 assessment of the core study) unless other approach is required by local practice.', 'p.', 'Required for females of childbearing potential only. May be repeated more frequently (i.e., between study visits) if required by local practices,', 'IRB/IECs or local regulations, if a menstrual cycle is missed, or if potential pregnancy is otherwise suspected. If more frequent testing is required, the', 'study site will provide the patient with further guidance and a home testing kit.', 'q.', 'Samples for INR, aPTT, and fibrinogen should be collected prior to all other blood samples.', 'r.', 'Lipid panel includes total cholesterol, HDL, LDL, triglycerides, lipoprotein (a), apolipoproteins (ApoB, ApoAl, and ApoB:ApoAl ratio), and', 'adiponectin.', 'S.', 'Cardiovascular risk panel includes NT-proBNP, BNP, and homocysteine.', 't.', 'Cardiovascular risk assessment includes alcohol use with an evaluation of average number of drinks consumed weekly, tobacco use with an evaluation', 'of average number of tobacco products consumed daily, central obesity, use of any lipid-lowering medication or any other CV agents, prior history of', 'CV events and diabetes, family history of premature CV disease (age <55 years for males and <65 years for females),', 'and', 'other', 'risks.', 'u.', 'Hematology includes RBC, WBC with differential, hemoglobin, hematocrit, and platelet count.', 'V.', 'At all visits, subjects must attend study sites after fasting for at least 9 hours (water and concomitant medications are permitted). Chemistry panel', 'includes urea nitrogen, creatinine, fasting glucose, calcium, sodium, potassium, chloride, total protein, total bilirubin, direct bilirubin, indirect bilirubin,', 'ALT, AST, alkaline phosphatase, GGT, and albumin.', 'W. Glycosylated hemoglobin will be assessed at Visits 2, 6, 8, and 10 only for subjects with a confirmed diagnosis of diabetes mellitus prior to Visit 2', '(Week 26). If a diagnosis of diabetes mellitus is confirmed after Visit 2 (Week 26), then HbA1c will be assessed at all subsequent visits as indicated in', 'the Schedule of Events.', 'X. Urinalysis includes specific gravity, pH, protein, glucose, ketones, blood, and leukocyte esterase.', 'y. The Visit 1 (OLE Baseline/Week 24) PK samples are the last samples to be collected in the core studies. These samples must be collected prior to', 'administration of OKZ, and the samples will be analyzed and included in the data set of the core study in which the subject participated, according', 'to', 'the', 'procedures detailed in the core study protocol. The PK sample will not be analyzed as part of the OLE data set.', 'z.', 'If chest X-ray (both posteroanterior and lateral) was performed within 8 weeks, the assessment should not be repeated at the scheduled visit.', 'aa. At Visit 1 (OLE Baseline/Week 24), Subject Diary will be distributed, and subjects will be trained to properly complete the Subject Diary.', 'At', 'Visit', '1', '(OLE Baeline/Week 24) and at each scheduled visit during the open-label Treatment Period (Visits 2 through 9), the Investigator', 'will', 'provide', 'the', 'subject with preprinted dates for each dose of study treatment that will be administered prior to the next scheduled visit. Following each administration', 'of study treatment, the subject will record the date, time, and location of each study treatment administration; the identity of the person who', 'administered the study treatment; any problems experienced during the injection; and any complaints, signs, or symptoms that occur during or after the', 'injection. Investigators will collect and review the Subject Diary at Visits 2 (Week 26) through 10 (EoT/Week 106).', 'Amendment 2: 06 March 2019', '49', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '5.2', 'Discussion of Study Design', 'After completing the 24-week double-blind Treatment Period in 1 of the 3 core studies, an', 'estimated 1880 subjects will be randomized to 1 of 2 open-label treatment groups:', '1. OKZ 64 mg q4w: SC injection of OKZ 64 mg q4w + MTX', '2. OKZ 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX', 'Subjects will be randomized based on the treatment received in the core studies. Subjects', 'who received OKZ (q2w or q4w) in the core study in which they participated (including', 'subjects who received placebo in Study CL04041025 and were re-randomized to OKZ at', 'Week 16) will receive the same OKZ treatment regimen in the OLE study. Subjects who', 'received placebo (Study CL04041022 and Study CL04041023) or adalimumab', '(Study CL04041023) in the core study in which they participated will be randomized in a', '1:1 ratio to OKZ 64 mg q2w or OKZ 64 mg q4w regimens in the OLE study.', \"The total duration of OKZ treatment will depend on the subject's treatment assignment in the\", 'core studies:', 'Subjects randomized to OKZ in the 3 core studies (CL04041022, CL04041023, and', 'CL04041025) will complete 106 total weeks of treatment with OKZ.', 'Subjects randomized to placebo in Study CL04041022 and to placebo or adalimumab', 'in Study CL04041023 will complete 82 total weeks of treatment with OKZ.', 'Subjects randomized to placebo in Study CL04041025 will transition to OKZ at Week', '16 and complete 8 weeks of double-blind treatment with OKZ during the core study;', 'these subjects will complete 90 total weeks of treatment with OKZ.', 'Subcutaneous injections of OKZ 64 mg will be administered q2w or q4w throughout the', 'open-label Treatment Period, and all subjects (and their caregivers, if applicable) will be', 'trained at Visit 1 (OLE Baseline/Week 24) to administer OKZ (see Section 6.8).', 'Administration of study treatment will be observed by study site staff during the first 2', 'scheduled visits (Visit 1 [Week 24] and Visit 2 [Week 26] for subjects receiving OKZ 64 mg', 'q2w, and Visit 1 [Week 24 and Visit 3 [Week 28] for subjects receiving OKZ 64 mg q4w).', 'Detailed guidance on study treatment administration procedures will be provided in the', 'Pharmacy Manual and Subject Leaflet.', 'For the first 12 weeks (up to Visit 4 [Week 36]) of the open-label Treatment Period, all', 'subjects will be required to remain on a stable dose of background MTX at 15 to 25 mg/week', '(or >10 mg/week if there is documented intolerance to higher doses) with a stable route of', 'Amendment 2: 06 March 2019', '50', 'Confidential']\n\n###\n\n", "completion": "END"}